Remepy was founded by Or Shoval in 2022.

Who are Remepy's investors?

Remepy's investors include 97212 Ventures, fresh.fund, IT-Farm Corporation, NFX, O.G. Venture Partners, PsyMed Ventures, Samsung Next, Supernode Ventures and 4 more.

How much funding has Remepy raised?

Remepy has disclosed $36M raised across 1 of its 2 known rounds.

Remepy

Founded 2022 · 86 employees on LinkedIn · 12 known investors

Find your way into Remepy

Paths you didn't know you had: your email and LinkedIn already hold routes to the Remepy team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Remepy develops "Hybrid Drugs" that combine pharmaceuticals with targeted digital interventions to deliver personalized and adaptive therapies for patients. It operates in the digital health and biotech space, aiming to treat conditions through a combination of biology, behavior, and technology.

AI & Machine Learning Biotech Digital Health

Founders & leadership

Remepy was founded in 2022 by Or Shoval.

Or Shoval Co-Founder & Co-CEOCo-founder and co-CEO of Remepy, which develops hybrid therapies combining pharmaceuticals with digital interventions to treat patients through integrated biological and behavioral mechanisms.

Amir AmediFounder

Eran EtamFounder

Michal TsurFounder

Investors · 12

97212 Ventureslisted by 97212 VenturesNew York · $150K – $500K

How we know: 97212 Ventures's portfolio page · funding news · the VCSheet dataset · Not right? Tell us

fresh.fundlisted by fresh.fund

How we know: funding news · Not right? Tell us

IT-Farm Corporationlisted by IT-Farm CorporationTokyovia Julien Nguyen · inferred

NFXlisted by NFXSan Francisco · $250K – $5M

How we know: a partner's Signal profile · funding news · Not right? Tell us

O.G. Venture Partnerslisted by O.G. Venture PartnersTel Aviv-Yafo · $5M – $15M

How we know: the VCSheet dataset · Not right? Tell us

PsyMed Ventureslisted by PsyMed VenturesBerkeley

How we know: PsyMed Ventures's portfolio page · funding news · Not right? Tell us

Samsung Nextlisted by Samsung NextMountain View · $100K – $5M

How we know: Samsung Next's portfolio page · Not right? Tell us

Supernode Ventureslisted by Supernode VenturesNew York · $500K – $1.3M

How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Vine Ventureslisted by Vine VenturesNew York · $1M – $10M

How we know: Vine Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

Key1 CapitalreportedHerzliya

How we know: funding news · Not right? Tell us

M VenturesreportedAmsterdam · $10.8M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Qumra CapitalreportedTel Aviv · $15M – $30M

How we know: funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

$36M disclosed across 1 of 2 rounds · 2026

$36MSeries AAug 2026 · 5 sources
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 3

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

BiosapienBiosapien develops treatments for cancer that are delivered locally to shrink tumors, relieve symptoms, and reduce the need for surgeries.

Remedy PlanRemedy Plan is a biopharmaceutical company developing drugs that target NAMPT, an essential enzyme dysregulated in more than 20 diseases including cancer. Its lead clinical candidate, RPT1G, is a hyperbolic inhibitor designed to reduce NAMPT activity while avoiding the toxicity that has limited earlier attempts.

Companies working in the same space as Remepy.

Frequently asked questions

What does Remepy do?: Remepy develops "Hybrid Drugs" that combine pharmaceuticals with targeted digital interventions to deliver personalized and adaptive therapies for patients. It operates in the digital health and biotech space, aiming to treat conditions through a combination of biology, behavior, and technology.
Who founded Remepy?: Remepy was founded by Or Shoval in 2022.
Who are Remepy's investors?: Remepy's investors include 97212 Ventures, fresh.fund, IT-Farm Corporation, NFX, O.G. Venture Partners, PsyMed Ventures, Samsung Next, Supernode Ventures and 4 more.
How much funding has Remepy raised?: Remepy has disclosed $36M raised across 1 of its 2 known rounds.